Use of Individualized Starting Dose and Niraparib Hematologic Adverse Event Management Costs in Ovarian Cancer
Whitney S. Graybill,Ignace Vergote,Bhavana Pothuri,Maarit Anttila,David M. O'Malley,Domenica Lorusso,Ashley F. Haggerty,Michel Fabbro,John K. Chan,Florian Heitz,Lyndsay J. Willmott,Ilan Bruchim, Ying Zhuo,Purificacion Estevez-Garcia,Bradley J. Monk,Hannelore Denys,Anja Knudsen,Anna Tinker,Luis Manso Sanchez,Diane Provencher,Maria Pilar Barretina-Ginesta, John Hartman, Donna Booth,Antonio Gonzalez-Martin JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH（2025）
关键词
cost management,maintenance therapy,niraparib,ovarian cancer,PARP inhibitor
AI 理解论文
溯源树
样例
